Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2022 | Assessing capmatinib for lung cancer

Shobhit Baijal, MBBS, MRCP, MRCP, The University Hospital Birmingham NHS Trust, Birmingham, UK, discusses recent advances in the lung cancer treatment landscape including capmatinib, which targets MET exon 14 skipping (METex14) mutations in lung cancer. The accelerated approval process devised by regulatory authorities has enabled more drugs to be used in the clinic and Dr Baijal additionally highlights novel checkpoint inhibitors that may be approved in the UK. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.

Disclosures

Dr Baijal has received honoraria from: Abbvie, Amgen, AstraZeneca, Boehringer Ingleheim, Bristol Myers-Squibb, Chugai, Daiichi Sankyo, FoundationOne, GlaxoSmithKline, Janssen, Lilly, Merck Serono, Novartis, Pierre Fabre, Pfizer, Roche, Servier, Sanofi and Takeda.